Rare diseases
Investigational molecules
Locations
703 conditions with trials, the busiest first
3 898 trials across Europe, recruiting first
Study of cemiplimab with chemoradiotherapy for patients with locally advanced cervical cancer
ItalyTesting continuous versus intermittent treatment with cetuximab, fluorouracil, folinic acid, and irinotecan in patients with newly diagnosed metastatic colorectal cancer
GermanyA Study of Ivosidenib and Azacitidine for Patients Over 55 with Acute Myeloid Leukemia and IDH1 Mutation in Complete Remission
FranceA study of pembrolizumab and lenvatinib for patients with high risk locally advanced cervical cancer after chemoradiotherapy and brachytherapy
The NetherlandsTesting UCPVax vaccine with or without pembrolizumab and temozolomide in patients with unmethylated MGMT glioblastoma after initial treatment
FranceStudy of pirtobrutinib combined with immuno-chemotherapy for previously untreated patients with symptomatic chronic lymphocytic leukemia
FranceEvaluation of Lung Function Using Xenon Gas with CT Imaging in Lung and Breast Cancer Patients Receiving Radiotherapy
BelgiumStudy of tamoxifen loading dose and Ki67 response in breast cancer patients before surgery (ENDO-67)
The NetherlandsStudy of ipilimumab, nivolumab, temozolomide and capecitabine in patients with chemotherapy-resistant metastatic colorectal cancer with specific genetic markers
DenmarkStudy of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery
BelgiumStudy of MIDRIX-LUNG immunotherapy combined with anti-PD-1 treatment in patients with metastatic non-small-cell lung cancer
BelgiumStudy of vinorelbine and cisplatin with radiation therapy for patients with castration- and taxane-resistant prostate cancer
EstoniaThe therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
